Early-stage cancer-fighting startup raises pre-seed, launches under Houston life science leader

ready to grow

Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

From Your Site Articles
Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston medical device company secures $57.7M to fund journey to FDA approval, commercialization

fresh funding

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

Atul Varadhachary of Fannin joins the Houston Innovators Podcast. Photo via LinkedIn

Houston innovator plays the long game of life science innovation with optimized capital efficiency

HOUSTON INNOVATORS PODCAST EPISODE 222

Commercializing a life science innovation that has the potential to enhance or even save the lives of millions of patients is a marathon, not a sprint. That's how Atul Varadhachary thinks of it, and he's leading an organization that's actively running that race for several different early-stage innovations.

For over a decade, Fannin has worked diligently to develop promising life science innovations — that start as just an idea or research subject — by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The model is different from what you'd see at an accelerator or incubator, and it also varies from the path taken by an academic or research institution.

The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary, managing director at Fannin, says on the Houston Innovators Podcast.



Fannin addresses what Varadhachary calls a twin bottleneck in Houston's life science innovation ecosystem. Not only does Houston not attract the funding biotech startups need desperately to grow their companies, but hiring is a major issue as the city isn't home to an established labor pool of experienced product developers within the industry.

"The challenge is that product development is more complex — it requires innovation, but that's not sufficient. When you ask people why we lag in the product development in the life sciences — although we are home to the largest medical center in the country, we don't even make list of top 10 biotech clusters — the usual answer is that we don't have enough biotech investors," Varadhachary says.

"But that puts the cart before the horse," he continues. "Investors invest in people not just ideas. Although we have an amazing pool of researchers and clinicians, we lack experienced product developers."

In more ways than one, Fannin is addressing this problem. For all of its several ongoing programs, Fannin acts as the leadership team for the technologies. Its core employees — there are about 20 currently — work on all of the companies, which are developing a range life science innovations, from Brevitest, a point-of-use immunoassay platform, to Procyrion, an intra-aortic pump for congestive heart failure patients.

Fannin's programs also range in stage, which Varadhachary outlines on the show to be three different phases. The earliest stage programs will have Fannin's team working directly on early testing, product development, and grant writing, while the later stage programs will have built out a dedicated team and raise venture investment.

Another way Fannin is addressing Houston's lack of life science product developers is through its Fannin Talent Development Program, which has given around 350 individuals an opportunity to gain critical product development experience.

With 10 years under its belt, Fannin — as well as the greater Houston life science innovation ecosystem — is at a point where it can soon produce exits needed to firm up Houston as a life science leader.

"Clearly, we've got the base elements required to be a successful ecosystem, and they continue to grow," Varadhachary says of Houston. "Typically you need one or two really big success stories — especially if those success stories result in a company being sold, leaving behind experienced product developers with money in their pockets — that's often what will supercharge the next cycle of development. I'm hoping that will happen in Houston in the next five years, decade, or so."

Houston-based Procyrion has closed a $30 million round — doubling its total funding to date. Getty Images

Houston medical device company closes $30 million round

Follow the money

A clinical-stage medical device company based in Houston has rounded up $30 million for its Series D funding. Procyrion Inc.'s round was lead by Bluebird Ventures — a new funding partner for the company.

Procyrion is developing a blood pump, called the Aortix™ system, that's optimized for patients with heart and kidney failure. Joining in on the round with Bluebird are return investors, including Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. This round has now more than doubled the company's total funding, bringing that figure now to $59 million.

"Of the more than 1 million patients per year in the U.S. admitted to the hospital with acute decompensated heart failure, 25 to 30 percent also have worsening renal function," says Eric S. Fain, president and CEO of the company, in a release. "These are typically the most difficult to treat patients with high mortality and rehospitalization rates."

The funds, Fain says, will go toward advancing the medical device, specifically enhancing the system's ability to decongest cardio renal patients in the company's pilot program.

"Today there is a major gap in effective therapies that are available to treat these critically ill patients, and as such, there is a significant opportunity to improve patient outcomes," Fain continues in the release. "The Aortix device is uniquely designed and positioned in the body to simultaneously decrease the workload of the heart and improve kidney function."

The Aortix device is a solution for patients who haven't seen success from medical therapy, but don't have the immediate need for a transplant or more drastic solution. The device is thinner than a pencil, the release says, and can be inserted in a matter of minutes in a cath-lab setting. The size and ease of application could be transformational for the large population of heart patients that would need it.

In addition to the funds, Jeff Bird, managing director of Bluebird Ventures, will join the company's board of directors.

"The Procyrion Aortix device provides an elegant solution for managing heart failure, a serious and difficult-to-treat problem," says Bird in the release. "We are excited to work with this experienced team as they begin clinical testing."


The device is thinner than a pencil and can be inserted in less than 10 minutes. Photo via procyrion.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

6 Houston entrepreneurs land on coveted Inc. Female Founders 500 list

the future is female

Six Houston female entrepreneurs and innovators were named to the 2026 Female Founders 500 list.

The annual list compiled by Inc. Magazine recognizes female founders based in the U.S. who have built businesses that have moved their industries forward. The group collectively generated approximately $12.3 billion in 2025 revenue and $12.2 billion in funding to date, according to Inc. Five Houstonians were named to the list last year.

"Each year, we are increasingly amazed by the extraordinary leaders on our Inc. Female Founders 500 list," Bonny Ghosh, editorial director at Inc., said in a news release. "The honorees on this year's list include innovators in AI, beauty and wellness trendsetters winning devoted fans, and nonprofit leaders making a real impact in their communities. Together, they're showing all of us what trailblazing female leadership looks like."

The Houston founders are:

  • Sassie Duggleby, CEO and co-founder of Houston space tech and engine company Venus Aerospace. Duggleby also serves on the Texas Space Commission board of directors.
  • Stephanie Murphy, CEO and executive chairman of Aegis Aerospace, which provides space services, spaceflight product development, and engineering services. Murphy also serves as chair of the Texas Aerospace Research and Space Economy Consortium Executive Committee.
  • Laureen Meroueh, CEO and founder of Hertha Metals, which has developed a cost-effective and energy-efficient process that converts low-grade iron ore of any format directly into molten steel or high-purity iron in a single step.
  • LaToshia Norwood, managing partner of L'Renee & Associates (LRA), a full-service project management consulting firm.
  • Lauren Rottet, president and founding principal of Rottet Studio, an international architecture and design firm focused on corporate, lifestyle and hospitality projects
  • Nina Magon, founder and CEO of Nina Magon Studio / Nina Magon Consumer Products, a residential and commercial interior design company. She also co-founded KA Residences earlier this year.

"Grateful to be recognized again on the Inc. Female Founders 500," Duggleby said in a LinkedIn post. "The best part of building Venus Aerospace has been working with an incredible team pushing the boundaries of flight—and helping bring more women into aerospace along the way.

Meroueh, whose company emerged from stealth last year, voiced a similar push for bringing more women into the fold.

"We've seen a 7x jump in female-led IPOs over the last decade, from just two in 2014 (less than 1% of all IPOs) to 14 in 2024 (nearly 9% of all IPOs). Progress is happening," Meroueh shared in a LinkedIn post. "Yet, less than 1% of venture funding in hard tech goes to female-founded companies. But as my friend Ana Kraft says, the right man for the job may be a woman."

Twenty-nine Texas female founders made this list, including Amber Venz Box, founder of the Dallas-based LTK shopping platform, and Cheryl Sew Hoy, CEO and founder of Austin-based Tiny Health, a fast-growing at-home microbiome health platform. See the full list of winners here.

NASA clears Artemis moon rocket for April launch with 4 astronauts

3, 2, 1...

NASA has cleared its moon rocket on for an April launch with four astronauts after completing the latest round of repairs.

The 322-foot (98-meter) rocket will roll out of the hangar and back to the pad at Florida's Kennedy Space Center, leading to a launch attempt as early as April 1. It will mark humanity's first trip to the moon in more than 50 years.

The Artemis II crew should have blasted off on a lunar flyaround earlier this year, but fuel leaks and other problems with the Space Launch System rocket interfered.

Although NASA managed to plug the hydrogen fuel leaks at the pad in February, a helium-flow issue forced the space agency to return the rocket to the Vehicle Assembly Building for repairs, bumping the mission to April.

The space agency has only six days at the beginning of April to launch before standing down until April 30 into early May.

"It's a test flight and it is not without risk, but our team and our hardware are ready,” NASA's Lori Glaze told reporters at the end of the two-day flight readiness review.

Glaze and other NASA officials declined to provide the risk probabilities for the upcoming mission.

History has shown that a new rocket has essentially a 50% chance of success, said John Honeycutt, chair of the mission management team.

There's so much gap since the only other SLS flight — more than three years ago without anyone on board — that it's difficult to understand any risk assessment numbers, Honeycutt said.

“It's not the first flight," Glaze said. "But we're also not in a regular cadence. So we definitely have significantly more risk than a flight system that's flying all the time.”

Late last month NASA's new administrator, Jared Isaacman, announced a major overhaul of the Artemis program to speed things up and, by doing so, reduce risk.

Dissatisfied with the slow pace and lengthy gaps between lunar missions, he added an extra practice flight in orbit around Earth for next year. That is now the new Artemis III, with the moon landing by two astronauts shifted to Artemis IV. Isaacman is targeting one and maybe even two lunar landings in 2028.

NASA's Office of Inspector General warned in an audit that the space agency needs to come up with a rescue plan for its lunar crews. Landing near the moon's south pole will be riskier than it was for the Apollo astronauts closer to the equator given the rough polar terrain, according to the report.

The report cited the lunar landers as the top contributor for potential loss of crew during the first few Artemis moon landings. It listed the space agency’s loss-of-crew threshold at 1-in-40 for lunar operations and 1-in-30 for Artemis missions overall.

Contracted by NASA to provide the moon landers for astronauts, Elon Musk's SpaceX and Jeff Bezos' Blue Origin have accelerated work in order to meet the new 2028 target date. The inspector general's office said many technical challenges remain including refueling their landers in orbit around Earth before flying to the moon.

NASA sent 24 astronauts to the moon during Apollo, 12 of whom landed on it. All but one of the moonshots — Apollo 13 — achieved their prime objectives. The program ended with Apollo 17 in 1972.

Kinder leads 19 Houstonians on Forbes' World's Billionaires List 2026

World's Richest 2026

According to Forbes, there has “never been a better time to be a billionaire” than in 2026, and the publication's newest World’s Billionaires List has revealed the 19 Houston billionaires that have risen among the wealthiest worldwide.

Kinder Morgan chairman Richard Kinder surpassed hospitality honcho Tilman Fertitta as the richest billionaire in Houston, ranking No. 232 on the global list with an estimated net worth of $13 billion. His net worth has grown by $2.4 billion since last year.

Fertitta, 68, may not be the richest Houstonian anymore, but his wealth is still on the rise. He ranked 268th on the list with an estimated net worth of $11.7 billion, up from $11.3 billion last year.

Out of the 390 billionaire newbies that made their debut onto the list this year, one of them calls Houston home: restaurateur and commodities trader Ignacio Torras. Torras, 61, is the founder and CEO of global commodities trading company Tricon Energy, and he owns Michelin-starred local restaurant BCN Taste & Tradition and its sister eatery MAD. But that's not all he spends his time doing, according to Forbes.

"In 2024 Torras launched a soccer tournament for neurodivergent players called the Genuine Cup," his profile said. "Last year 800 players and 30 teams from around the world played at Rice University stadium."

Torras debuted as No. 2600 on the list with an estimated net worth of $1.5 billion.

Houston-born multi-hyphenate superstar Beyoncé Knowles-Carter also staked a claim among the world's richest people in 2026. She ranked No. 3332 on the list with a net worth of $1 billion, thanks to her "years of music sales, touring and collecting art with her already-billionaire husband Jay-Z (estimated net worth: $2.8 billion)," Forbes said.

"The majority of pop star Beyonce’s net worth comes from her roughly three decades as a solo performer and a member of the girl-group Destiny's Child," her profile said. "She holds the record for the most Grammy wins ever, with 35, and won her first Album of the Year trophy in 2025. She and her billionaire husband Jay-Z purchased a $200 million Malibu mansion in 2023, in what was the most expensive home sale in California history."

Beyoncé also ranks No. 21 in the publication's separate list of The World's Celebrity Billionaires.

Here's how the rest of Houston's billionaires fared on this year's list:

  • Toyota mega-dealer Dan Friedkin: No. 279; $11.4 billion, up from $7.7 billion
  • Pipeline heir Randa Duncan Williams: tied for No. 323 with an estimated net worth of $10.2 billion, up from $9.3 billion in 2025. Fellow pipeline heirs Dannine Avara and Milane Frantz tied for No. 332 globally. Each has an estimated net worth of $10.1 billion, up from $9.2 billion. Scott Duncan ranks No. 353 with a $9.8 billion estimated net worth, up from $9 billion in 2025.
  • Oil tycoon Jeffery Hildebrand: No. 341; $10 billion, up from $7.7 billion
  • Houston Texans owner Janice McNair and family: No. 528; $7.3 billion, up from $6.2 billion
  • Energy exploration chief exec George Bishop of The Woodlands: No. 908; $4.7 billion, down from $5 billion
  • Westlake Corporation co-owners Albert Chao, James Chao and their families: tied for No. 1074; $4 billion, flat from 2025
  • Hedge fund honcho John Arnold: No. 1504; $2.8 billion, down from $2.9 billion
  • Perry Homes executive chair Kathy Britton: No. 1611; $2.6 billion, flat from 2025
  • Houston Astros owner Jim Crane: No. 1676; $2.5 billion, up from $2.4 billion
  • Former Houston Rockets owner Leslie Alexander: No. 1834; $2.3 billion, up from $1.9 billion
  • Mercedes-Benz mega-dealer Joe Agresti: No. 3185; $1.1 billion, flat from 2025
  • Frontier Airlines chairman William Franke: No. 3332; $1 billion, down from $1.2 billion

Elsewhere in Texas

Austin billionaire Elon Musk was declared the world's richest person for the second consecutive year, and Forbes said his “grip on the top spot is as strong as it’s ever been.”

“Musk became the first person to hit $500 billion in wealth, in October,” Forbes said. “Then $600 billion and $700 billion, within four days in December. Then $800 billion, in February.”

The Tesla, SpaceX, and xAI founder’s current net worth has skyrocketed to $839 billion — a shocking $497 billion more than his 2025 net worth.

In Dallas-Fort Worth, Walmart heiress Alice Walton has maintained her elite status as the world’s richest woman for the third year in a row. Walton is the 14th richest person on the planet with a current net worth of $134 billion, an eye-catching $33 billion higher than her 2025 net worth. She is the first American woman worth $100 billion, and one of only 20 “centi-billionaires” worldwide claiming 12-figure fortunes, also known as the "$100 Billion Club."

Koch Inc. stakeholder Elaine Marshall and her family are the richest Dallas residents, ranking No. 71 globally with an estimated net worth of $30.9 billion. Her net worth has grown by $2.6 billion since last year.

---

This article originally appeared on CultureMap.com.

View All Listings